As of October 1, breast cancer drug loses public funding. Patients must change therapy

As of October 1, a drug that for seven years successfully slowed advanced breast cancer in many patients has been removed from the reimbursement list. Women like Magdalena, in whom the therapy worked and allowed normal life — working and raising children — must now change treatment. Patients and doctors are outraged by the decision, as the drug was effective.